Along with individual lifestyle modifications, the potential association between antidiabetic medication given to T2D patients and CKD is firstly based on the oral intake of metformin and sodium glucose cotransporter 2 inhibitors (SGLT2 inhibitors), whereby the individual adjustment of glucose-lowering medication due to impaired renal function must always be considered and re-evaluated [2,51]. This evidence concerns the gene SLC5A2 and chronic kidney disease.